PT  - JOURNAL ARTICLE
AU  - Ruben D Restrepo
TI  - Use of Inhaled Anticholinergic Agents in Obstructive Airway Disease
DP  - 2007 Jul 01
TA  - Respiratory Care
PG  - 833--851
VI  - 52
IP  - 7
4099  - http://rc.rcjournal.com/content/52/7/833.short
4100  - http://rc.rcjournal.com/content/52/7/833.full
AB  - In the last 2 decades, anticholinergic agents have been generally regarded as the first-choice bronchodilator therapy in the routine management of stable chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma. Anticholinergics are particularly important bronchodilators in COPD, because the vagal tone appears to be the only reversible component of airflow limitation in COPD. The inhaled anticholinergics approved for clinical use are synthetic quaternary ammonium congeners of atropine, and include ipratropium bromide, oxitropium bromide, and tiotropium bromide. This article reviews the most current evidence for inhaled anticholinergics in obstructive airway disease and summarizes outcomes reported in randomized controlled trials.